SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2008, for Spherix Incorporated. The Company operates two principal segments following the August 2007 sale of its InfoSpherix subsidiary: BioSpherix, focused on the development of tagatose (marketed as "Naturlose") for Type 2 diabetes treatment, and Health Sciences, a consulting business launched in July 2007. The Company is currently conducting a Phase 3 clinical trial for Naturlose.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2008 | Six Months Ended June 30, 2008 |
|---|---|---|
| Revenue | $263,151 | $406,059 |
| Net Loss | $(1,198,273) | $(3,112,507) |
| Loss Per Share (Basic & Diluted) | $(0.08) | $(0.22) |
| Cash and Cash Equivalents | $7,926,655 (as of June 30, 2008) | |
| Short-term Investments | $4,054,076 (as of June 30, 2008) | |
| Working Capital | $11.7 million | |
| Total Debt | None reported (Line of credit closed in 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased significantly from $3,769 in the prior year quarter to $263,151, driven entirely by the new Health Sciences consulting segment. BioSpherix revenue remains negligible ($5,000).
- Operating Expenses: Total operating expenses decreased slightly year-over-year for the quarter ($1.55M vs $1.95M) due to a relocation to a smaller facility in April 2008, despite increased R&D costs for the Phase 3 trial.
- Cash Position: Cash and cash equivalents decreased by approximately $7.9 million during the six-month period, primarily due to operating losses and the purchase of $4.05 million in short-term investments.
- Discontinued Operations: The prior year period included income from the InfoSpherix segment, which was sold in August 2007. Current periods reflect only continuing operations.
Outlook, Risks, and Management Commentary
- Clinical Trial Status: Patient recruitment for the Phase 3 Naturlose trial has been slower than expected. The Company terminated its agreement with a former Contract Research Organization (CRO) in March 2008 to take direct control of U.S. operations and signed a new CRO for an India-based portion of the trial to improve enrollment.
- Timeline: Management expects the Dose Range study to complete in 2009 and the Phase 3 trial in 2010.
- Liquidity: The Company expects to expend approximately $5 million over the next year on the clinical trial and related activities. It intends to finance these costs using proceeds from the InfoSpherix sale but may need to raise additional funds through stock sales if the trial is delayed or marketing efforts expand.
- NASDAQ Compliance Risk: On July 21, 2008, NASDAQ notified the Company that its stock price had closed below the $1.00 minimum bid price requirement for 30 consecutive days. The Company has until January 20, 2009, to regain compliance or face delisting. A reverse stock split is being considered.
Investor Verification Checklist
- Verify the current status and enrollment numbers of the Phase 3 clinical trial for Naturlose.
- Confirm the Company's plan to address the NASDAQ minimum bid price deficiency (e.g., reverse stock split approval).
- Monitor cash burn rate against the projected $5 million expenditure for the upcoming year.
- Assess the revenue sustainability of the Health Sciences consulting segment.
- Review the timeline for the potential $2 million escrow payment from the InfoSpherix sale (due November 2008).